H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on QURE stock, giving a Buy rating on October 2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising results from uniQure’s AMT-130 trials. The pivotal 3-year data from the Phase 1/2 trials in Huntington’s disease (HD) patients demonstrated significant clinical efficacy, with a notable slowing of disease progression and improvements in biomarkers. These results suggest that AMT-130 could become the first therapy to alter the disease’s natural course, marking a significant advancement in HD treatment.
Furthermore, the safety profile of AMT-130 remains favorable, with no new serious adverse events reported since December 2022, and the manageable nature of previous events. The combination of robust clinical outcomes, biomarker validation, and a clear regulatory path supports a potential U.S. launch in 2026. Reflecting these strengths, Trucchio raised the price target for uniQure to $110, reinforcing his confidence in the company’s commercial and therapeutic potential.
In another report released on October 2, Wells Fargo also reiterated a Buy rating on the stock with a $80.00 price target.